Matching articles for "COPD"

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • September 2, 2024;  (Issue 1710)
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce...
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Drugs for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 2, 2024;  (Issue 1710)
...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Med Lett Drugs Ther. 2024 Sep 2;66(1710):e143-7 | Show Full IntroductionHide Full Introduction

Ensifentrine (Ohtuvayre) for COPD

   
The Medical Letter on Drugs and Therapeutics • August 19, 2024;  (Issue 1709)
The FDA has approved ensifentrine (Ohtuvayre – Verona), an inhaled phosphodiesterase (PDE) 3 and 4 inhibitor, for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is the...
The FDA has approved ensifentrine (Ohtuvayre – Verona), an inhaled phosphodiesterase (PDE) 3 and 4 inhibitor, for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is the first dual inhibitor of PDE3 and PDE4 to be approved by the FDA, and the first inhaled drug with a new mechanism of action to be approved for treatment of COPD in more than 20 years.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):131-3 | Show Full IntroductionHide Full Introduction

Ryzneuta for Prevention of Febrile Neutropenia

   
The Medical Letter on Drugs and Therapeutics • August 19, 2024;  (Issue 1709)
Efbemalenograstim alfa-vuxw (Ryzneuta – Evive), a nonpegylated granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG2, has been approved by the FDA to decrease the...
Efbemalenograstim alfa-vuxw (Ryzneuta – Evive), a nonpegylated granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG2, has been approved by the FDA to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia. It is the first nonpegylated, long-acting G-CSF to become available in the US. Two pegylated, long-acting G-CSFs, pegfilgrastim (Neulasta, and biosimilars) and eflapegrastim (Rolvedon), are also available.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):134-5 | Show Full IntroductionHide Full Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several...
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and review articles on COPD treatment have been published in recent years. Treatment of acute exacerbations is not discussed here.
Med Lett Drugs Ther. 2020 Sep 7;62(1606):137-44 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
...
View the Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD
Med Lett Drugs Ther. 2020 Sep 7;62(1606):e146-7 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Corticosteroids for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
...
View the Comparison Table: Inhaled Corticosteroids for Treatment of COPD
Med Lett Drugs Ther. 2020 Sep 7;62(1606):e148-9 | Show Full IntroductionHide Full Introduction

Table: Correct Use of Inhalers for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
...
View the Table: Correct Use of Inhalers for COPD
Med Lett Drugs Ther. 2020 Sep 7;62(1606):e150-4 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
...
View the Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD
Med Lett Drugs Ther. 2020 Sep 7;62(1606):e144-5 | Show Full IntroductionHide Full Introduction

In Brief: Respiratory Depression with Gabapentinoids

   
The Medical Letter on Drugs and Therapeutics • June 1, 2020;  (Issue 1599)
The FDA has required new warnings in the labels of gabapentin (Neurontin, and others) and pregabalin (Lyrica, Lyrica CR, and generics) about the risk of life-threatening or fatal respiratory depression in...
The FDA has required new warnings in the labels of gabapentin (Neurontin, and others) and pregabalin (Lyrica, Lyrica CR, and generics) about the risk of life-threatening or fatal respiratory depression in patients with respiratory risk factors. Respiratory risk factors include chronic obstructive pulmonary disease (COPD) and concurrent use of opioids or other CNS depressants. Elderly patients are also at increased risk.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):81 | Show Full IntroductionHide Full Introduction

Duaklir Pressair: Another LAMA/LABA Inhaler for COPD

   
The Medical Letter on Drugs and Therapeutics • September 23, 2019;  (Issue 1581)
The FDA has approved Duaklir Pressair (Circassia), a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and the longacting beta2-adrenergic agonist (LABA)...
The FDA has approved Duaklir Pressair (Circassia), a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and the longacting beta2-adrenergic agonist (LABA) formoterol fumarate, for maintenance treatment of chronic obstructive pulmonary disease (COPD). Aclidinium/formoterol is the fifth LAMA/LABA combination to be approved in the US for this indication.
Med Lett Drugs Ther. 2019 Sep 23;61(1581):149-51 | Show Full IntroductionHide Full Introduction

Revefenacin (Yupelri) for COPD

   
The Medical Letter on Drugs and Therapeutics • January 28, 2019;  (Issue 1564)
The FDA has approved revefenacin (Yupelri – Mylan/Theravance Biopharma), a long-acting antimuscarinic agent (LAMA) administered once daily by standard jet nebulizer, for maintenance treatment of...
The FDA has approved revefenacin (Yupelri – Mylan/Theravance Biopharma), a long-acting antimuscarinic agent (LAMA) administered once daily by standard jet nebulizer, for maintenance treatment of chronic obstructive pulmonary disease (COPD). Revefenacin is the second nebulized LAMA to be approved for this indication; glycopyrrolate (Lonhala Magnair), which is administered twice daily with a portable handheld nebulizer, was the first.
Med Lett Drugs Ther. 2019 Jan 28;61(1564):14-5 | Show Full IntroductionHide Full Introduction

Trelegy Ellipta - A Three-Drug Inhaler for COPD

   
The Medical Letter on Drugs and Therapeutics • May 21, 2018;  (Issue 1547)
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate, the long-acting antimuscarinic agent (LAMA) umeclidinium, and the...
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate, the long-acting antimuscarinic agent (LAMA) umeclidinium, and the long-acting beta2-agonist (LABA) vilanterol. It is available as a dry powder inhaler for once-daily maintenance treatment of COPD and to reduce COPD exacerbations in patients with a history of exacerbations. Trelegy Ellipta is the first three-drug inhaler for treatment of COPD to become available in the US.
Med Lett Drugs Ther. 2018 May 21;60(1547):86-8 | Show Full IntroductionHide Full Introduction

Nebulized Glycopyrrolate (Lonhala Magnair) for COPD

   
The Medical Letter on Drugs and Therapeutics • April 23, 2018;  (Issue 1545)
The FDA has approved an inhalation solution formulation of the long-acting antimuscarinic agent (LAMA) glycopyrrolate (Lonhala Magnair – Sunovion) for maintenance treatment of chronic...
The FDA has approved an inhalation solution formulation of the long-acting antimuscarinic agent (LAMA) glycopyrrolate (Lonhala Magnair – Sunovion) for maintenance treatment of chronic obstructive pulmonary disease (COPD). The new formulation is delivered using a portable, handheld, electronic nebulizer. Glycopyrrolate is also available as a dry powder inhaler, both alone (Seebri Neohaler) and in combination with indacaterol (Utibron Neohaler), and as a metered-dose inhaler in combination with formoterol (Bevespi Aerosphere). Lonhala Magnair is the first nebulized LAMA to become available in the US.
Med Lett Drugs Ther. 2018 Apr 23;60(1545):72 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Short-Acting Bronchodilators for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • April 10, 2017;  (Issue 1518)
...
View the Comparison Table: Inhaled Short-Acting Bronchodilators for COPD
Med Lett Drugs Ther. 2017 Apr 10;59(1518):e62-3 | Show Full IntroductionHide Full Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • April 10, 2017;  (Issue 1518)
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated...
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated guidelines for treatment of COPD have been published in recent years.
Med Lett Drugs Ther. 2017 Apr 10;59(1518):57-62 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Long-Acting Bronchodilators for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • April 10, 2017;  (Issue 1518)
...
View the Comparison Table: Inhaled Long-Acting Bronchodilators for COPD
Med Lett Drugs Ther. 2017 Apr 10;59(1518):e64-5 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Inhaled Corticosteroids for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • April 10, 2017;  (Issue 1518)
...
View the Comparison Table: Some Inhaled Corticosteroids for COPD
Med Lett Drugs Ther. 2017 Apr 10;59(1518):e66 | Show Full IntroductionHide Full Introduction

Table: Correct Use of Inhalers for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • April 10, 2017;  (Issue 1518)
...
View the Table: Correct Use of Inhalers for COPD
Med Lett Drugs Ther. 2017 Apr 10;59(1518):e67-71 | Show Full IntroductionHide Full Introduction

Glycopyrrolate/Formoterol (Bevespi Aerosphere) for COPD

   
The Medical Letter on Drugs and Therapeutics • October 10, 2016;  (Issue 1505)
The FDA has approved a fixed-dose combination of the long-acting anticholinergic glycopyrrolate and the long-acting beta2-adrenergic agonist (LABA) formoterol (Bevespi Aerosphere – AstraZeneca)...
The FDA has approved a fixed-dose combination of the long-acting anticholinergic glycopyrrolate and the long-acting beta2-adrenergic agonist (LABA) formoterol (Bevespi Aerosphere – AstraZeneca) for long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Glycopyrrolate/formoterol is the fourth long-acting anticholinergic/LABA combination to be approved in the US, but the first to become available in a metered-dose inhaler. Glycopyrrolate/indacaterol (Utibron Neohaler), umeclidinium/vilanterol (Anoro Ellipta), and tiotropium/olodaterol (Stiolto Respimat) were approved earlier.
Med Lett Drugs Ther. 2016 Oct 10;58(1505):130-2 | Show Full IntroductionHide Full Introduction

Alternatives to Fluoroquinolones

   
The Medical Letter on Drugs and Therapeutics • June 6, 2016;  (Issue 1496)
The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects,...
The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects, generally outweighs their benefit for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. For these infections, the new labels will recommend reserving fluoroquinolones for patients with no other treatment options.
Med Lett Drugs Ther. 2016 Jun 6;58(1496):75-6 | Show Full IntroductionHide Full Introduction

Seebri Neohaler and Utibron Neohaler for COPD

   
The Medical Letter on Drugs and Therapeutics • March 28, 2016;  (Issue 1491)
The FDA has approved two new inhalers for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Seebri Neohaler (Novartis) contains the long-acting anticholinergic glycopyrrolate....
The FDA has approved two new inhalers for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Seebri Neohaler (Novartis) contains the long-acting anticholinergic glycopyrrolate. Utibron Neohaler (Novartis) contains both glycopyrrolate and the long-acting beta2-adrenergic agonist (LABA) indacaterol. Glycopyrrolate/indacaterol is the third fixed-dose combination of a long-acting anticholinergic and a LABA to become available in the US; umeclidinium/vilanterol (Anoro Ellipta) and tiotropium/olodaterol (Stiolto Respimat) were approved earlier.
Med Lett Drugs Ther. 2016 Mar 28;58(1491):39-41 | Show Full IntroductionHide Full Introduction

Tiotropium/Olodaterol (Stiolto Respimat) for COPD

   
The Medical Letter on Drugs and Therapeutics • November 23, 2015;  (Issue 1482)
The FDA has approved a fixed-dose, orally inhaled combination of the long-acting anticholinergic tiotropium and the long-acting beta2-adrenergic agonist olodaterol (Stiolto Respimat — Boehringer...
The FDA has approved a fixed-dose, orally inhaled combination of the long-acting anticholinergic tiotropium and the long-acting beta2-adrenergic agonist olodaterol (Stiolto Respimat — Boehringer Ingelheim) for long-term, once-daily, maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD). It is not approved for treatment of acute exacerbations of COPD or for treatment of asthma. Tiotropium (Spiriva Handihaler, Spiriva Respimat) and olodaterol (Striverdi Respimat) are also available separately for once-daily treatment of COPD.
Med Lett Drugs Ther. 2015 Nov 23;57(1482):161-2 | Show Full IntroductionHide Full Introduction

Fluticasone Furoate (Arnuity Ellipta) for Asthma

   
The Medical Letter on Drugs and Therapeutics • May 25, 2015;  (Issue 1469)
The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone...
The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone furoate is also available in combination with the long-acting beta2-agonist vilanterol as Breo Ellipta for treatment of asthma and COPD.
Med Lett Drugs Ther. 2015 May 25;57(1469):76-9 | Show Full IntroductionHide Full Introduction

Umeclidinium (Incruse Ellipta) for COPD

   
The Medical Letter on Drugs and Therapeutics • April 27, 2015;  (Issue 1467)
The FDA has approved Incruse Ellipta (GSK), a single-agent inhaler containing the long-acting anticholinergic umeclidinium, for once-daily maintenance treatment of chronic obstructive pulmonary disease...
The FDA has approved Incruse Ellipta (GSK), a single-agent inhaler containing the long-acting anticholinergic umeclidinium, for once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD). Umeclidinium was initially approved in combination with the long-acting beta2-adrenergic agonist vilanterol as Anoro Ellipta.
Med Lett Drugs Ther. 2015 Apr 27;57(1467):63-4 | Show Full IntroductionHide Full Introduction

Spiriva Respimat - An Oral Inhalation Spray for COPD

   
The Medical Letter on Drugs and Therapeutics • March 30, 2015;  (Issue 1465)
Tiotropium bromide, an inhaled long-acting anticholinergic available since 2004 as a dry powder inhaler (Spiriva Handihaler) for once-daily treatment of chronic obstructive pulmonary disease (COPD), has now...
Tiotropium bromide, an inhaled long-acting anticholinergic available since 2004 as a dry powder inhaler (Spiriva Handihaler) for once-daily treatment of chronic obstructive pulmonary disease (COPD), has now also been approved in an inhalation spray formulation (Spiriva Respimat – Boehringer Ingelheim). According to the manufacturer, the Respimat device improves delivery of tiotropium to the lungs because, unlike with the Handihaler, it is not dependent on the strength of the patient’s breath intake.
Med Lett Drugs Ther. 2015 Mar 30;57(1465):49-50 | Show Full IntroductionHide Full Introduction

Olodaterol (Striverdi Respimat) for COPD

   
The Medical Letter on Drugs and Therapeutics • January 5, 2015;  (Issue 1459)
Olodaterol (Striverdi Respimat – Boehringer Ingelheim), a new inhaled long-acting beta2-agonist, has been approved by the FDA for once-daily maintenance treatment of airflow obstruction in patients...
Olodaterol (Striverdi Respimat – Boehringer Ingelheim), a new inhaled long-acting beta2-agonist, has been approved by the FDA for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). It is not approved for treatment of acute exacerbations of COPD or for treatment of asthma. Olodaterol is the third long-acting beta2-agonist to be approved by the FDA for once-daily use; indacaterol (Arcapta Neohaler), which is available as a single agent, and vilanterol, which is available only in fixed-dose combinations with the long-acting anticholinergic umeclidinium (Anoro Ellipta) or the corticosteroid fluticasone furoate (Breo Ellipta), were approved earlier.
Med Lett Drugs Ther. 2015 Jan 5;57(1459):1-3 | Show Full IntroductionHide Full Introduction

Anoro Ellipta: An Inhaled Umeclidinium/Vilanterol Combination for COPD

   
The Medical Letter on Drugs and Therapeutics • April 14, 2014;  (Issue 1440)
The FDA has approved an inhaled fixed-dose combination of the long-acting anticholinergic umeclidinium (ue mek" li din' ee um) and the long-acting beta2-adrenergic agonist (LABA) vilanterol (Anoro Ellipta...
The FDA has approved an inhaled fixed-dose combination of the long-acting anticholinergic umeclidinium (ue mek" li din' ee um) and the long-acting beta2-adrenergic agonist (LABA) vilanterol (Anoro Ellipta – GSK/Theravance) for once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD). Anoro Ellipta is the first product available in the US that combines two long-acting bronchodilators in a single delivery device.
Med Lett Drugs Ther. 2014 Apr 14;56(1440):30-1 | Show Full IntroductionHide Full Introduction

Breo Ellipta: An Inhaled Fluticasone/Vilanterol Combination for COPD

   
The Medical Letter on Drugs and Therapeutics • September 2, 2013;  (Issue 1424)
The FDA has approved an inhaled fixed-dose combination (Breo Ellipta – GSK/Theravance) of the corticosteroid fluticasone furoate and the long-acting beta2-adrenergic agonist (LABA) vilanterol...
The FDA has approved an inhaled fixed-dose combination (Breo Ellipta – GSK/Theravance) of the corticosteroid fluticasone furoate and the long-acting beta2-adrenergic agonist (LABA) vilanterol trifenatate for once-daily treatment of chronic obstructive pulmonary disease (COPD).
Med Lett Drugs Ther. 2013 Sep 2;55(1424):69-71 | Show Full IntroductionHide Full Introduction

Drugs for Asthma and COPD

   
The Medical Letter on Drugs and Therapeutics • August 1, 2013;  (Issue 132)
INHALATION DEVICES — Metered-dose inhalers (MDIs) require coordination of inhalation with hand-actuation of the device. Valved holding chambers (VHCs) or spacers help some patients, especially young...
INHALATION DEVICES — Metered-dose inhalers (MDIs) require coordination of inhalation with hand-actuation of the device. Valved holding chambers (VHCs) or spacers help some patients, especially young children and the elderly, use MDIs effectively. VHCs have one-way valves that prevent the patient from exhaling into the device, minimizing the need for coordinated actuation and inhalation. Spacers are tubes or chambers placed between the canister and a face mask or mouthpiece, which also avoids the need to coordinate actuation and inhalation. Both VHCs and spacers retain the larger particles emitted from the MDI, decreasing their deposition in the oropharynx and leading to a higher proportion of small respirable particles being inhaled.
Treat Guidel Med Lett. 2013 Aug;11(132):75-86 | Show Full IntroductionHide Full Introduction

Indacaterol (Arcapta Neohaler) for COPD

   
The Medical Letter on Drugs and Therapeutics • April 30, 2012;  (Issue 1389)
The FDA has approved indacaterol (in´´ da ka´ ter ol; Arcapta Neohaler – Novartis), an inhaled long-acting beta2-agonist, for once-daily maintenance treatment of airflow obstruction in patients with...
The FDA has approved indacaterol (in´´ da ka´ ter ol; Arcapta Neohaler – Novartis), an inhaled long-acting beta2-agonist, for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Indacaterol is not approved for treatment of exacerbations of COPD or for treatment of asthma. It has been available in Europe as Onbrez Breezhaler since 2009.
Med Lett Drugs Ther. 2012 Apr 30;54(1389):33-5 | Show Full IntroductionHide Full Introduction

Roflumilast (Daliresp) for COPD

   
The Medical Letter on Drugs and Therapeutics • July 25, 2011;  (Issue 1369)
Roflumilast (Daliresp – Forest), an oral phosphodiesterase 4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients with severe chronic obstructive pulmonary...
Roflumilast (Daliresp – Forest), an oral phosphodiesterase 4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
Med Lett Drugs Ther. 2011 Jul 25;53(1369):59-60 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Obstructive Pulmonary Disease

   
The Medical Letter on Drugs and Therapeutics • November 1, 2010;  (Issue 99)
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and decrease complications of the disease...
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and decrease complications of the disease such as acute exacerbations. Other guidelines for treatment of this condition have been published or updated in recent years.
Treat Guidel Med Lett. 2010 Nov;8(99):83-8 | Show Full IntroductionHide Full Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • September 1, 2010;  (Issue 97)
The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals...
The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals is discussed in the text that follows. Some drugs are recommended here for indications that have not been approved by the FDA.
Treat Guidel Med Lett. 2010 Sep;8(97):65-70 | Show Full IntroductionHide Full Introduction

Safety of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD)

   
The Medical Letter on Drugs and Therapeutics • May 31, 2010;  (Issue 1339)
Two combinations of an inhaled corticosteroid with an inhaled long-acting beta2-agonist are approved by the FDA for use in patients with COPD: fluticasone/salmeterol (Advair Diskus) and...
Two combinations of an inhaled corticosteroid with an inhaled long-acting beta2-agonist are approved by the FDA for use in patients with COPD: fluticasone/salmeterol (Advair Diskus) and budesonide/formoterol (Symbicort). A Medical Letter reader has questioned the safety of using corticosteroid inhalers in patients with this disorder. No single-agent inhaled corticosteroid inhaler is approved for this indication.
Med Lett Drugs Ther. 2010 May 31;52(1339):41-2 | Show Full IntroductionHide Full Introduction

Drugs for Tobacco Dependence

   
The Medical Letter on Drugs and Therapeutics • September 1, 2008;  (Issue 73)
Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. The greater the number of office visits and the longer the counseling time, the higher the smoking...
Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. The greater the number of office visits and the longer the counseling time, the higher the smoking cessation rates have been.
Treat Guidel Med Lett. 2008 Sep;6(73):61-5 | Show Full IntroductionHide Full Introduction

Formoterol (Perforomist) for COPD

   
The Medical Letter on Drugs and Therapeutics • November 19, 2007;  (Issue 1274)
Formoterol fumarate (Perforomist - Dey), a long-acting beta2-agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of bronchoconstriction associated with...
Formoterol fumarate (Perforomist - Dey), a long-acting beta2-agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of bronchoconstriction associated with chronic obstructive pulmonary disease (COPD). Arformoterol (Brovana), the (R, R)-enantiomer of formoterol, was approved earlier this year for the same indication.
Med Lett Drugs Ther. 2007 Nov 19;49(1274):94-5 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Obstructive Pulmonary Disease

   
The Medical Letter on Drugs and Therapeutics • November 1, 2007;  (Issue 63)
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such...
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such as acute exacerbations and cor pulmonale. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines developed by the World Health Organization and the National Heart, Lung and Blood Institute were updated in 2006. The American Thoracic Society and the European Respiratory Society jointly developed guidelines for COPD in 2004.
Treat Guidel Med Lett. 2007 Nov;5(63):95-100 | Show Full IntroductionHide Full Introduction

Arformoterol (Brovana) for COPD

   
The Medical Letter on Drugs and Therapeutics • July 2, 2007;  (Issue 1264)
Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary...
Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary disease (COPD). Arformoterol is the (R,R)-enantiomer of formoterol (Foradil), which is available as a powder for inhalation and was recently also approved as a solution for nebulization (Perforomist - Dey; available fall 2007)
Med Lett Drugs Ther. 2007 Jul 2;49(1264):53-5 | Show Full IntroductionHide Full Introduction

Tiotropium (Spiriva) for COPD

   
The Medical Letter on Drugs and Therapeutics • May 24, 2004;  (Issue 1183)
Tiotropium bromide inhalation powder (Spiriva HandiHaler - Boehringer Ingelheim), a long-acting anticholinergic agent, has been approved by the FDA for once-daily maintenance treatment of bronchospasm...
Tiotropium bromide inhalation powder (Spiriva HandiHaler - Boehringer Ingelheim), a long-acting anticholinergic agent, has been approved by the FDA for once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). Available in Europe since 2002, it is the first long-acting inhaled anticholinergic drug for treatment of COPD. Ipratropium bromide (Atrovent), an anticholinergic used four times daily, has been available in the US for many years.
Med Lett Drugs Ther. 2004 May 24;46(1183):41-2 | Show Full IntroductionHide Full Introduction